Other Plasma Proteins (e.g., Albumin)
Hypovolaemia, Severe haemorrhaging, Volume expansion, Thrombosis (Intensive Care)
ApprovedCommercial
Key Facts
Indication
Hypovolaemia, Severe haemorrhaging, Volume expansion, Thrombosis (Intensive Care)
Phase
Approved
Status
Commercial
Company
About LFB
The LFB Group is a leading French biopharmaceutical laboratory dedicated to providing healthcare professionals with critical medicinal products derived from plasma or recombinant proteins. Operating with a strong public health mission, it serves as an essential link between plasma donors and patients, developing and manufacturing biomedicines for serious, chronic, and rare diseases. With nearly 3,100 employees worldwide and sales of €599.6 million in 2024, LFB is a key player in ensuring therapeutic sovereignty in France while expanding its international footprint across Europe, the Americas, and other global markets.
View full company profile